Market Research Report
Specialty Generics - Global Market Outlook (2016-2022)
|Published by||Stratistics Market Research Consulting||Product code||521523|
|Published||Content info||170 Pages
Delivery time: 1-2 business days
|Specialty Generics - Global Market Outlook (2016-2022)|
|Published: February 1, 2017||Content info: 170 Pages||
According to Stratistics MRC, the Global Specialty Generics market is estimated at $XX billion in 2016 and is expected to reach $XX billion by 2022 growing at a CAGR of XX% from 2016 to 2022. Increase in prevalence of cancer across the globe and favourable government policies are the factors fuelling the market growth. Whereas factors like lack of skilled professionals is restraining the market. Oncology segment is anticipated to grow at higher CAGR during forecast period owing to the expirations of existing patent. North America accounted for the highest market share as compared to other regions owing to favourable government policies. Asia pacific region is expected to show healthy growth rate during forecast period.
Some of the key players in the market include Valeant Pharmaceuticals International, Inc., Novartis, Pfizer Inc., Turing Pharmaceuticals, Teva Pharmaceutical Ltd., Mylan N.V., Akorn, Inc., Mallinckrodt, Intellipharmaceutics and Alvogen.
Route of Administration Covered:
Disease Indications Covered:
Distribution Channels Covered:
What our report offers: